Partner Courtenay Brinckerhoff contributed an article to Life Sciences Intellectual Property Review, “Will You, Won’t You, Will You Join the Dance?” on July 30, 2015. In the article, Brinckerhoff discusses the implications and unanswered questions for the biosimilars framework after the U.S. Court of Appeals for the Federal Circuit ruled in Amgen v. Sandoz that biosimilar applicants can opt out of the “patent dance.”
Author(s)
Related Insights
July 10, 2025
Foley Viewpoints
One Big Beautiful Bill Act Permanently Increases the Lifetime Estate, Gift and GST Tax Exclusion
On July 4, 2025, President Trump signed into law the One Big Beautiful Bill Act (OBBBA). The OBBBA extended and may permanent many key…
July 10, 2025
Foley Viewpoints
FTC's "Click-to-Cancel" Rule Invalidated
The Federal Appeals Court for the 8th Circuit invalidated the Federal Trade Commission's (FTC) “click-to-cancel” (aka “negative option”)…
July 10, 2025
Foley Viewpoints
Trump Administration Passes the One Big Beautiful Bill Act
On July 4, 2025, President Trump signed H.R. 1—referred to as the One Big Beautiful Bill Act (OBBBA). The OBBBA extends and makes…